Authors Posts by Head Editor

Head Editor

5007 POSTS 18 COMMENTS

1 1057

Research published in the International Journal of Drug Policy has discovered that people taking psychoactive medications and drugs for conditions such as chronic pain seem to prefer medical cannabis to other drugs, including sedatives, opioids, and antidepressants.

Many analysts have expressed worry about the use of opioids to treat chronic pain. More than 183,000 people died of prescription opioid overdoses between 1999 and 2015 in the U.S. Some research, such as a recent study that looked at states with medical cannabis laws, suggests access to medical marijuana could reduce opioid abuse. The research used survey data from 271 people registered to purchase medical cannabis. Participants answered 107 questions covering demographic data, use of cannabis, reliance on other drugs, and health history.

Survey respondents had been prescribed drugs for a range of reasons, including chronic pain, mental health conditions, and gastrointestinal issues. Overall, 63% reported using marijuana instead of prescription drugs. The most common drug class for which participants substituted cannabis was opioids, accounting for 30% of the total. Sixteen percent of participants used marijuana to replace benzodiazepines, and 12% used marijuana instead of antidepressants.

Cannabis was also a popular replacement for potentially addictive nonmedical drugs. Twenty-five percent of respondents used cannabis instead of drinking alcohol, 12% used it instead of cigarettes or tobacco, and 3% replaced illicit drugs with cannabis. The study’s authors suggest side effects, concerns about addiction, and level of safety figure prominently among the decision to use cannabis instead of other medications. Some medical marijuana users report cannabis works better than more traditional prescription medications.

The study found individuals often faced challenges to accessing medical cannabis. More than half were charged for their marijuana prescription, with 25% paying more than $300 for the prescription. Some participants still purchased marijuana from unregulated sources in spite of having a prescription.

0 440

Canabo Medical Inc. Opens New Clinic in Chilliwack, BC

Dr. Neil Smith, Executive Chairman of Canabo Medical Inc. stated, “We are expecting several new clinic openings in the near future.” Smith explained that clinics often take several months to mature in new markets, requiring time for patients and referring doctors to be made aware of and understand the service Canabo provides. “The clinics that will open this spring will contribute significantly to Canabo’s patient numbers by the end of 2017.”

Canabo wholly owns and operates 14 Cannabinoid Medical Clinics, or CMClinics, Canada’s most respected and largest referral-only clinics for medical cannabis. Since beginning operations in 2014, Canabo now has clinic locations in Toronto, Barrie, St. Catharine’s, Burlington, Stoney Creek, Ottawa, Hamilton, Halifax, St. John’s, Moncton, Kingston, Edmonton, Calgary, and Chilliwack. The company has plans to open an additional 8 clinics in 2017.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

0 296

Momentum Builds for Blue Line Protection Group’s Vaulting and Transportation Services

 Blue Line Protection Group, Inc. (BLPG), a leading security, transportation and risk mitigation solutions provider for financial institutions servicing the legal cannabis industry, continues to experience unprecedented expansion in its vaulting and currency processing division with double-digit growth during the first two months of 2017.

Blue Line experienced an increase of 67 percent in the total dollar value of client currency deposits from January to February 2017.  “Since our vaulting and processing division began operations last year, we’ve seen a tremendous increase in the number of clients served by our transportation and currency processing services,” said Daniel Allen, Blue Line’s CEO.  Revenue for processing those deposits grew 78 percent during the same period.

Blue Line provides vaulting, currency processing and compliance investigations solutions to banks and credit unions.  Blue Line serves the financial institutions’ clients by securely transporting their currency assets from their business locations to Blue Line’s secure vaulting and processing facility in Denver, Colorado.

“Our initial increase in client deposits of 292 percent from October 2016 to January 2017 demonstrated that there was a vital need for our currency processing services,” added Mr. Allen.  “The fact that we continue to experience tremendous growth month-to-month shows that our vaulting and processing division has gained a solid foothold and continues to attract new clients, adding to our already established base.”

Besides currency processing, Blue Line also saw continued growth in its coin, currency and ATM fulfillment services for its clients, surging ahead with a 41 percent increase in February compared with the previous month.  Revenue for providing these change and ATM fulfillment services jumped 127 percent from January to February.

“Not only do we see an increased demand for our fulfillment services, our rapid expansion has also resulted in a triple-digit revenue increase for these services,” added Mr. Allen.  “The reason for the demand is simple: Blue Line provides superior value, service and communication to our clients.  We’re with our clients every step of the way, helping protect their cash flow so they can provide uninterrupted service to their customers.”

Blue Line’s transportation division continued its month-to-month growth, as well.  The number of client currency packages collected and delivered by Blue Line’s transportation division increased 68 percent from January to February.  “Our trained and licensed personnel provide a level of customer service and communication unmatched by other armored service providers,” added Mr. Allen.

Blue Line continues to offer its compliance investigations services, helping its financial institution clients comply with their “know your customer” requirements.  “We’ve been able to assist banks and credit unions with our on-site, independent, compliance assessment services,” added Mr. Allen.  “We help reduce business transactional fraud, limiting the risks to financial institutions offering banking services to high-risk operations like the legal cannabis industry.”

About Blue Line Protection Group, Inc.

Blue Line Protection Group provides consulting, armed security, compliance and investigations, transportation and secure vaulting services to banks, businesses and government entities who need to protect their assets, licenses and clients.  Blue Line serves banks and credit unions by providing currency processing and transportation solutions, and its risk mitigation services help financial institutions serving cash-intensive industries comply with federal “know your customer” mandates.  For more information, visit www.BlueLineProtectionGroup.com.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

0 301

Two Rivers To Host Investor Conference Call

Interested participants are invited to call-in 15 minutes prior to the scheduled call. The phone number is 888-298-3511 (or international: +1 719-325-2458), conference ID 7339870 and a playback of the call will be available for the 2 weeks after the call by dialing 888-203-1112 (or international: +1 719-457-0820). Time will be set aside to ask questions of Management. Participating in this call will be Two Rivers’ President and CEO, Wayne Harding and Vice President of Finance and Accounting, Bill Gregorak.

Commenting on the upcoming call, President and CEO Wayne Harding stated, “This is an important update call. Two Rivers has very positive developments happening now. This investor call will provide our shareholders an opportunity to be better informed and ask questions of management.”

About Two Rivers
Two Rivers assembles its water assets by acquiring irrigated farmland with senior water rights. Two Rivers current farm operations convert feed crop farmland into fruit and vegetable crop production in Pueblo County Colorado. In November 2012, Colorado legalized the personal use and cultivation of marijuana. As a result, Two Rivers is providing greenhouses and processing facilities for licensed marijuana growers in Colorado on land with water rights not used for fruit and vegetable crop production. Two Rivers’ long term strategy focuses on the value of our water assets and how to monetize water for the benefit of its stakeholders, including communities near where our water assets are located.

Forward-Looking Statements
This news release contains “forward-looking statements,” as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors, including the inherent uncertainties associated with developing and acquiring land and water resources. There can be no assurance Two Rivers will be able to initiate and operate its grow facilities in accordance with its business plans. These forward-looking statements are made as of the date of this news release, and Two Rivers assume any obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements.

1 965

The emergence of the cannabis industry has led to the creation of sub-industries within it and this has created numerous opportunities for investors.

One sub-industry we find to be very attractive is biotech and this is due to the potential development of numerous billion dollar products.

The potential medical benefits of cannabis can no longer be ignored as agencies like the National Cancer Institute (NCI) continue to recognize its potential. In 2015, the NCI updated its website to include various studies that reveal how cannabis may inhibit tumor growth by killing cells.

Betting on Biotech

Although the biotech industry offers a lot of opportunity, it presents even more risk. When we look at biotech investment opportunities, we look for companies that possess a competitive or unique advantage over their peers.

Last week, one of the biotech companies we have been monitoring closely, Nemus Bioscience (NMUS), announced that it will be advancing the development of a human-dosage suppository formulation of NB1222 with Catalent Pharma Solutions. The product candidate is the proprietary prodrug of tetrahydrocannabinol (THC).

NB1222 has been synthetically manufactured and is being developed to treat and manage chemotherapy-induced nausea and vomiting (CINV). Nemus also plans on advancing this prodrug into formulation activity for the glaucoma indication using its NB1111 candidate molecule.

Today, Nemus signed a development agreement with United Kingdom-based Nanomerics to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, the active component of Nemus drug candidate NB1111 being developed for glaucoma.

The goal of the agreement is to conduct initial studies assessing the preparation of clinical-grade eye drops using the patented Molecular Envelope Technology (MET) developed by Nanomerics.

According to the agreement, work will commence on a future date determined by Nemus. The date is expected to be related with its development plans and corporate objectives.

Nemus Bioscience CEO Brian Murphy said, “Should we find success in formulating NB1111 using Nanomerics’ MET, we could also examine its application using our proprietary Nemus ophthalmic analogue of CBD (NB2222). Our company objective is to establish strategic partnerships utilizing a diverse cannabinoid-based ocular platform to address multiple types of eye disease.”

A Stock to Watch

Nemus Bioscience is an interesting company to watch due to its valuation, product pipeline, and its strategic partnership with the University of Mississippi. The university has been the sole provider of cannabis for medical research through a partnership with the National Institutes of Health since 1968.

We are favorable on this update as it shows further execution by Nemus. The company’s strategic relationship with Federal agencies makes it an attractive opportunity for investors and a stock to watch.

0 702

Rocky Mountain High Brands Announces Retirement of Shares

Rocky Mountain High Brands, Inc. (RMHB), a fully reporting consumer goods company specializing in hemp-infused food and beverage products and a naturally high alkaline water, announced today that the Officers and Directors are voluntarily returning 25,000,000 shares of the Company’s Common Stock to the Treasury.

Michael Welch, President and Chief Executive Officer of Rocky Mountain High Brands, Inc., said, “As part of our commitment to our Company and its shareholders, the Officers and Directors of Rocky Mountain High Brands are voluntarily surrendering 25,000,000 shares of Common Stock to the Company’s Treasury. In exchange, the Company has established a qualified stock plan known as the Company’s 2017 Incentive Plan.  These actions will take these shares out of the market while the Company is in a critical expansion mode.”

Welch continued, “With the recent announcement by the Company of the planned acquisition of the former Catskill Mountain resort facility in upstate New York, as well as other potential acquisitions that the Company is currently reviewing with LSW Holdings, LLC, we have found it necessary to restructure both our common and preferred stock.  Later today, we will file an Information Statement on Schedule 14C with the SEC announcing the increase in the number of authorized shares of preferred stock to 20,000,000 and common stock to 950,000,000.  These increases are necessary for establishing strategic relationships with corporate partners and acquiring or investing in complementary businesses or products. It is important to note that the Company has no plans to reverse the stock and, in fact, has plans to expand the shareholder base world-wide.”

About Rocky Mountain High Brands:

ROCKY MOUNTAIN HIGH BRANDS, INC., is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low-calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots. The Company recently launched a naturally high alkaline spring water, Eagle Spirit Spring Water.

For interested investors, our stock symbol is RMHB.

For ordering information please visit: LiveRockyMountainHigh.com

For corporate information please visit: RockyMountainHighBrands.com

For information on our high alkaline water visit: EagleSpiritWater.com

For Rocky Mountain High Distribution Contact:

Chuck Smith (972) 955-0964
chuck@rockymountainhighbrands.com

Visit us on Facebook: https://www.facebook.com/rockymountainhighbrands?fref=nf

Visit us on Twitter:
#GetYourHempOn

Visit us at Investors Hangout: http://investorshangout.com/Rocky-Mountain-High-Brands-Inc-RMHB-69150/

Investors Hangout is the only authorized Investors blog page for Rocky Mountain High Brands, Inc.

Safe Harbor Act: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic business conditions and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

0 849

Quality Of Cannabis Issued By Government Affecting Scientists’ Research

The quality of the cannabis the United States government provides to scientists may be impacting the results of their studies, experts say. The issue made national headlines after Dr. Sue Sisley, a researcher with the Multidisciplinary Association for Psychedelic Studies (MAPS), shared photos of the marijuana provided by the only facility licensed by the Drug Enforcement Administration to produce cannabis for clinical research. The facility is located at the University of Mississippi and is run by the National Institute on Drug Abuse (NIDA).


Click Here Now To Read Full Article


Marijuana As A Glaucoma Treatment; Does It Really Work?

 

Research has shown that cannabinoids can alleviate glaucoma-related symptoms because they lower the intraocular pressure (IOP) and have neuroprotective actions. For example, in 1971, one of the first studies of its kind found ingestion of cannabis lowers IOP by 25 to 30%. Despite the findings from early research, very few ophthalmologists support the use of medical cannabis in patients with early to mid-stage glaucoma. The main issue ophthalmologists have with marijuana is that the potential adverse effects, particularly smoking cannabis, outweigh the short term benefits. For example, smoking can lead to unstable intraocular pressure, which heightens the risk of permanent vision loss.


Click Here Now To Read Full Article


 

Marijuana Industry Takes A Step Forward Towards Validity And Long-Term Stability

The marijuana industry is getting ready to take a step forward in its venture for validity and long-term stability. The American Society for Testing and Materials (ASTM International) recently announced that it will put a committee of industry representatives and experts together to create a set of guidelines in six technical areas: Indoor and outdoor horticulture and agriculture, Quality management systems, Laboratory standards, Processing and handling, Security and transportation, Personal training/ assessment and credentialing.


Click Here Now To Read Full Article


1 1487

The quality of the cannabis the United States government provides to scientists may be impacting the results of their studies, experts say. The issue made national headlines after Dr. Sue Sisley, a researcher with the Multidisciplinary Association for Psychedelic Studies (MAPS), shared photos of the marijuana provided by the only facility licensed by the Drug Enforcement Administration to produce cannabis for clinical research. The facility is located at the University of Mississippi and is run by the National Institute on Drug Abuse (NIDA).

Doctor Sisley is studying marijuana as a treatment for post-traumatic stress disorder (PTSD) in United States veterans. Sisley stated, “It didn’t resemble cannabis. It didn’t smell like cannabis.” We asked Jake Browne, who is a cannabis critic for the Denver Post’s marijuana news site, the Cannabist, and co-founder of The Grow-Off, a statewide cannabis growing competition, what he thought about the cannabis seen in the photos. Browne said, “It’s unlike any weed I’ve ever seen, and that includes really low grade stuff I’d get as a kid in Iowa. It looks like it’s mostly stems and leaves, and that stuff is better for giving you headaches than getting you high.”

Brown stated, “It should be covered in trichomes, or frosty-looking resin glands, and have much higher density than what Dr. Sisley is working with. As a rule of thumb, you want your buds intact and no smaller than a piece of popcorn, with a green or purple hue to them.” Additionally, PBS reported that some of the samples provided by NIDA were contaminated with mold and others didn’t match the chemical potency Sisley had requested for the study. She stated, “One sample, billed as having a 13% level of THC, the main psychoactive compound in marijuana, had just 8% when tested at the independent facility in Colorado.”

According to the Washington Post, recreational cannabis available in Colorado ranges from an average of about 19% THC to 30% or more. Sisley stated, “There’s no telling how many subjects in past studies were exposed. Honestly, it seems like [the National Institute on Drug Abuse] is playing a joke on Dr. Sisley,” Browne stated. “High potency cannabis can cause anxiety and paranoia, so when you’re talking about a study on PTSD, that seems very relevant to me. With pot in our state regularly testing at three times the potency of what they supplied to her, it’s not acceptable.” The only facility approved by the DEA to grow marijuana for clinical studies is at the University of Mississippi and is run by the National Institute on Drug Abuse (NIDA).

0 565

A Senate panel approved a proposal permitting South Carolina farmers to grow industrial hemp through a pilot program set up with the South Carolina Department of Agriculture. The proposal would create a system to regulate the growing, selling, and importation of industrial hemp in conjunction with the Department of Agriculture and for study by an academic facility, such as Clemson University. Senators recently took testimony from law enforcement officials who cited issues with the Senate proposal and instead encouraged them to allow the House legislation to work its way through the system.

Executive director with the S.C. Sheriffs’ Association, Jarrod Bruder, said though law enforcement typically has concerns about industrial hemp, all parties worked together to reach a compromise in the House. The House version limits the number of farmers in the first years of the program to fifteen and allows law enforcement to do random testing of the plants to ensure marijuana is not being grown. Bruder stated, “We got to a point in the House where, I wouldn’t say we endorse it, but it got to a point where we could hold our nose and say it was good. It was something that we could live with.”

The measure passed a Senate Agriculture and Natural Resources subcommittee three to one, with members saying they planned to amend the proposal in the full committee to address the concerns of law enforcement. Senator Rex Rice voted against the proposal. In addition to oil, hemp can be made into products such as rope, clothing, paper, canvas, soap, and even some food and drinks, such as butter and milk. The Senate proposal is similar to one that will be going to the full House Agriculture, Natural Resources and Environmental Affairs Committee.

0 540

MassRoots Announces One Million Registered Users

“MassRoots registering one million users is a significant milestone made possible by the strong support of our shareholders, tireless work of the MassRoots team, and passion of cannabis consumers worldwide,” stated MassRoots Chairman and CEO, Mr. Isaac Dietrich. “In the coming days, we’ll be releasing a revamped website and updates to our mobile application that will significantly enhance our user experience and can be immediately deployed to our vast user base. With the 4/20 holiday season rapidly approaching, we’re preparing for a surge of web traffic, media coverage and user registrations that MassRoots has historically experienced this time of year. We look forward to continuing to expand our market share of cannabis consumers and dispensaries to further drive shareholder value.”

About MassRoots
MassRoots is one of the largest technology platforms for the regulated cannabis industry. The Company’s mobile apps enable consumers to make educated cannabis purchasing decisions through community-driven reviews. MassRoots is proud to be affiliated with the leading businesses and organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. For more information, please visit MassRoots.com/Investors.

Forward-looking Statements
Certain matters discussed in this announcement contain statements, estimates and projections about the growth of MassRoots’ business, potential partnerships, new features, and related business strategy. Such statements, estimates and projections may constitute forward-looking statements within the meaning of the federal securities laws. Factors or events that could cause our actual results to differ may emerge from time to time. MassRoots undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The recipient of this information is cautioned not to place undue reliance on forward-looking statements.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/massroots-announces-one-million-registered-users-300425858.html

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements